

November 9, 2011

Launch of the Critical Path to TB Drug Regimens' Advisory Panel

The Critical Path to TB Drug Regimens (CPTR) is pleased to announce the launch of its inaugural Advisory Panel. This committee is CPTR's senior advisory body. The Advisory Panel will provide guidance to CPTR's Coordinating Group – helping CPTR navigate the complicated technical, political, and economic challenges that challenge the field of TB drug development. Members will also help catalyze global support for TB drug combination testing and champion the new regulatory pathways and other tools needed to accelerate the development and delivery of dramatically improved treatment to TB patients worldwide.

The inaugural members of the Advisory Panel are among the most well-respected thought leaders in the TB field, and include regulators, donors, bioethicists, advocates, industry representatives and others from around the world. Each inaugural Advisory Panel member will advise the initiative for at least a one-year term. Members include:

- **Kenneth Castro, MD**
Director, Division of TB Elimination, US CDC
- **Hans-Georg Eichler, MD, MSc**
Senior Medical Officer, European Medicines Agency
and Chair of CPTR Advisory Panel
- **Anthony S. Fauci, MD**
Director, National Institute of Allergy and Infectious Diseases, US NIH
- **Mark Harrington**
Executive Director, Treatment Action Group
- **Murray Lumpkin, MD, MSc**
Advisor and Representative for Global Issues, US FDA
- **Charles Mgone, MD, PhD**
Executive Director, EDCTP
- **Trevor Mundel**
President, Global Health, Bill & Melinda Gates Foundation
- **Carol Nyirenda**
Executive Director, Community Initiative for TB, HIV/AIDS & Malaria.
- **Mario Raviglione, MD**
Director, Stop TB Department, World Health Organization
- **Jerome Singh, BA, LLB, LLM, PhD, MHSc**
Head, Ethics and Law, CAPRISA
- **Paul Stoffels, MD**
Worldwide Chairman, Pharmaceuticals, Johnson & Johnson
- **Tachi Yamada, MD**, Executive Vice President and Board Member, Takeda Pharmaceuticals

- **Elias Zerhouni, MD**
President, Global Research & Development, Sanofi

“The CPTR Advisory Panel offers a broad array of expertise that is necessary to advance a new paradigm for TB drug development,” said Raymond Woosley, MD, PhD, President and CEO of C-PATH and a member of CPTR’s Coordinating Group. “The members of CPTR look forward to working with the Advisory Panel to speed development and delivery of new TB regimens.”

Co-founded by the Bill & Melinda Gates Foundation, the Critical Path Institute, and the TB Alliance, CPTR is fostering collaboration around a critical public health need – dramatically reducing the time it takes to develop new TB drug regimens. Advisory Panel members will help CPTR accelerate access to urgently needed TB drugs, and ensure shorter, safer, and more effective multi-drug treatments reach patients worldwide as quickly as possible.